Clinical scoring of EAE-affected IgG control and EphA4Fc treated mice.

<p>Paralysis in EAE-affected mice was assessed by clinical scoring up to 23 days post-immunisation. <b>A)</b> EphA4Fc treated mice had a delayed onset of clinical symptoms (2-Way Repeated Measures ANOVA with Bonferroni post-hoc test **<i>p</i><0.01, ***<i>p</i><0.001). <b>B)</b> The highest clinical score reached within 23 days post-immunisation was similar in control and treated mice (unpaired t-test, *<i>p</i><0.05). Results show mean±SEM of <i>n</i> = 27 IgG control and <i>n</i> = 26 EphA4Fc treated mice.